-
About UsWe are a company specializing in the research, development, and production of pharmaceutical and functional chemicals, dedicated to delivering innovative and high-quality products.
-
ESGPlacing a strong emphasis on sustainable development and continuously improve our quality management system, we actively implement these principles in our production processes and uphold our corporate social responsibility.
-
Join UsFind the job you’re suited to. Jingyu Group urgently needs passionate individuals like you who love pharmaceuticals and chemistry to join us!
06
2023
-
02
Model Worker | Gao XingFa: Striving for Excellence and Innovation
From individuals to companies, a sense of responsibility signifies an unwavering drive to forge ahead. Gao XingFa, an entrepreneur, is the Chairman of Whale Pharmaceuticals, a fine chemical high-tech enterprise that integrates research, production, and sales. Following the development strategy of "Beijing R&D, Liu Chuan Production, Global Sales," Whale Pharmaceuticals aims to become a globally outstanding and leading pharmaceutical industrial company in China.
Gao XingFa, Chairman of Baiyin Jingyu New Pharmaceutical Co., Ltd.
Innovation is the inexhaustible driving force for sustainable business growth. Since the establishment of our R&D center in 2020, we have submitted three patent applications to the National Intellectual Property Administration, with three more in the pipeline. We have successfully transferred two patents, and we anticipate filing five to ten patent applications annually in the future.
[Chairman of Baiyin Jingyu New Pharmaceutical Co., Ltd. Gao XingFa]
"One of the products manufactured in our workshop is Dapagliflozin, a drug specifically for treating type 2 diabetes. It is a globally leading drug, exceptionally rare in terms of raw materials, with minimal side effects and rapid efficacy. We have a research institute in Beijing, where we have been conducting research and development for three to five years. We have already conducted small-scale trials in our laboratory and will soon commence final trials".
Dapagliflozin is an effective medication for diabetes treatment and is an innovative drug under the UK-based AstraZeneca. It can be used as a monotherapy to improve blood sugar control in adults with type 2 diabetes. Dapagliflozin is the first sodium-glucose co-transporter-2 (SGLT2) inhibitor to be marketed in China. Currently, no domestic companies are selling this product. It is the only diabetes drug included in medical insurance coverage, helping to lower blood sugar levels through sugar excretion in urine in addition to dietary and exercise improvements. It has the added benefit of weight reduction and is also safe for cardiovascular health.
According to the list of encouraged generic drugs published by the National Medical Products Administration's Department of Drug Policy and Basic Drug System, the active pharmaceutical ingredients of Empagliflozin and Dapagliflozin developed and produced by Whale Pharmaceuticals belong to the second batch of encouraged generic drugs. By addressing the shortage of clinically needed drugs and certain generic drugs, our efforts have a positive and proactive impact.
"As the company has grown, unity, innovation, and research and development have been crucial factors. We have a research and development team and institute based in Beijing," says Gao XingFa, Chairman of Baiyin Jingyuxin Pharmaceutical Co., Ltd.
Gao XingFa, recognized as a Model Worker in Jingyuan County, has led Whale Pharmaceuticals in collaboration with several domestic pharmaceutical companies to accelerate the marketing and sales of innovative and generic drugs. This contributes to alleviating the suffering of patients and making a modest contribution to national healthcare reforms.
Zhang Renyue, an employee at Whale Pharmaceuticals, shares, "Mr. Gao is diligent and pragmatic in his work. Whenever we face challenging tasks, he is at the forefront, actively helping us solve problems. He cares deeply about his employees and serves as an exemplary role model."
Reported by Ma Zhenzhen and Duan Yuling from Jingyuan County Integrated Media Center.
keyword:
Other Developments
Long-Term Partner Sumitomo Chemical Senior Executives Visit Whale Corp
On March 8, 2023, Jingyu Group received a visit from senior management of Sumitomo Chemical, a long-term important partner. Although the three-year pandemic has blocked offline meetings, it has never affected cooperation and communication between the two sides. Looking forward to closer and deeper cooperation between both parties in the future !
03-31
2023
Whale Corporation
Email: info@whalecorporation.com
Address: 2nd Floor, Zhongdu Technology Building, No. 35 Xisihuan South Road, Fengtai District, Beijing, China
Follow Us